Another Stelara Settlement Revealed As Accord Files US Biosimilar
Partnered DMB-3115 Ustekinumab Candidate Is Accepted By FDA And Gains Entry Date
A further US settlement agreement over Stelara has been struck with originator Janssen, with Accord BioPharma revealing the deal at the same time as it announced that a filing for its Dong-A/Meiji Seika-partnered DMB-3115 biosimilar ustekinumab candidate had been accepted for review by the FDA.
